Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
2008-07-15
2008-07-15
Allen, Marianne P. (Department: 1647)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
C435S069100, C435S320100, C435S325000, C514S012200, C536S023500
Reexamination Certificate
active
07399829
ABSTRACT:
The present invention relates to novel, soluble, recombinant variants RANKL (Receptor Activator of Nuclear Factor—κB Ligand) proteins, which may be expressed solubly inE. coli,variants that act as RANKL antagonists, and methods for generating the same.
REFERENCES:
patent: 5843678 (1998-12-01), Boyle
patent: 6017729 (2000-01-01), Anderson et al.
patent: 6242213 (2001-06-01), Anderson
patent: 6316408 (2001-11-01), Boyle
patent: 6645500 (2003-11-01), Halkier et al.
patent: 2002/0061525 (2002-05-01), Rodrigo et al.
patent: 2003/0013651 (2003-01-01), Lam et al.
patent: WO 99/12965 (1999-03-01), None
patent: WO 99/29865 (1999-06-01), None
patent: WO 00/15807 (2000-03-01), None
patent: WO 00/15807 (2000-03-01), None
patent: WO 00/67034 (2000-11-01), None
patent: WO 01/25277 (2001-04-01), None
patent: WO 01/42298 (2001-04-01), None
patent: WO 01/64889 (2001-09-01), None
patent: WO 2004/089982 (2001-10-01), None
patent: WO 02/18445 (2002-03-01), None
patent: WO 02/36141 (2002-05-01), None
patent: WO 03/006154 (2003-01-01), None
patent: WO 03/029420 (2003-04-01), None
patent: WO 03/033663 (2003-04-01), None
patent: WO 03/033664 (2003-04-01), None
patent: WO 03/059281 (2003-07-01), None
patent: WO 2004/081043 (2004-09-01), None
patent: WO 2005/035570 (2005-04-01), None
Wells, Additivity of mutational effects in proteins. Biochemistry 29:8509-8517 (1990).
Ngo et al., The Protein Folding Problem and Tertiary Structure Prediction, pp. 433-440 and 492-495 (1994).
Adler SH, and Turka LA. “Immunotherapy as a means to induce transplantation tolerance.” Curr Opin Immunol. Oct. 2002;14(5):660-5.
Alatalo SL, et al., “Rapid screening method of osteoclast differentiation in vitro that measures tartrate-resistant acid phosphatase 5b activity secreted into the culture medium.” Clin Chem. Nov. 2000;46(11):1751-4.
Anderson DM, et al., “A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function.” Nature. Nov. 13, 1997;390(6656):175-9.
Arron Jr, and Choi Y. “Bone versus immune system.” Nature. Nov. 30, 2000;408(6812):535-6.
Atkins GJ, et al. “Osteoprotegerin inhibits osteoclast formation and bone resorbing activity in giant cell tumors of bone.” Bone. Apr. 2001;28(4):370-7.
Bachmann MF, and Kopf M. “Balancing protective immunity and immunopathology.” Curr Opin Immunol. Aug. 2002;14(4):413-9.
Bianchi L, et al., “A cluster region of AP-1 responsive elements is required for transcriptional activity of mouse ODC gene by hepatocyte growth factor.” Arch Biochem Biophys. May 1, 2002;401(1):115-23.
Bodmer JL, et al., “The molecular architecture of the TNF superfamily.” Trends Biochem Sci. Jan. 2002;27(1):19-26.
Childs LM, et al., “In vivo RANK signaling blockade using the receptor activator of NF-kappaB:Fc effectively prevents and ameliorates wear debris-induced osteolysis via osteoclast depletion without inhibiting osteogenesis.” J Bone Miner Res. Feb. 2002;17(2):192-9.
Collin-Osdoby P, et al. “Receptor activator of NF-kappa B and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis.” J Biol Chem. Jun. 8, 2001;276(23):20659-72.
Compston JE. “Bone marrow and bone: a functional unit.” J Endocrinol. Jun. 2002;173(3):387-94.
Curotto de Lafaille Ma, and Lafaille JJ. “CD4(+) regulatory T cells in autoimmunity and allergy.” Curr Opin Immunol. Dec. 2002;14(6):771-8.
Darnay BG, et al., “Characterization of the intracellular domain of receptor activator of NF-kappaB (RANK). Interaction with tumor necrosis factor receptor-associated factors and activation of NF-kappab and c-Jun N-terminal kinase.” J Biol Chem. Aug. 7, 1998;273(32):20551-5.
Deyama Y, et al. “Histamine stimulates production of osteoclast differentiation factor/receptor activator of nuclear factor-kappaB ligand by osteoblasts.” Biochem Biophys Res Commun. Oct. 25, 2002;298(2):240-6.
Fata JE, et al., “The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development.” Cell. Sep. 29, 2000;103(1):41-50.
Gao YH, et al. “Potential role of cbfa1, an essential transcriptional factor for osteoblast differentiation, in osteoclastogenesis: regulation of mRNA expression of osteoclast differentiation factor (ODF).” Biochem Biophys Res Commun. Nov. 27, 1998;252(3):697-702.
Goater JJ, et al., “Efficacy of ex vivo OPG gene therapy in preventing wear debris induced osteolysis.” J Orthop Res. Mar. 2002;20(2):169-73.
Good CR, et al., “Immunohistochemical study of receptor activator of nuclear factor kappa-B ligand (RANK-L) in human osteolytic bone tumors,” J Surg Oncol. Mar. 2002;79(3):174-9.
Gori F, et al., “The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated.” Endocrinology. Dec. 2000;141(12):4768-76.
Gowen M et al., “Emerging therapies for osteoporosis,” Exp. Opin. on Emerging Drugs 2000 5(1):1-43.
Gravallese EM, et al., “The role of TNF-receptor family members and other TRAF-dependent receptors in bone resorption.” Arthritis Res. 2001;3(1):6-12.
Hofbauer LC, et al., “Interleukin-1beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells.” Bone. Sep. 1999;25(3):255-9.
Hofbauer LC, et al., “Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases.” Cancer. Aug. 1, 2001;92(3):460-70.
Honore P, et al., “Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord,” Nat Med. May 2000;6(5):521-8.
Hotokezaka H, et al. “U0126 and PD98059, specific inhibitors of MEK, accelerate differentiation of RAW264.7 cells into osteoclast-like cells.” J Biol Chem. Dec. 6, 2002;277(49):47366-72.
Hsu H, et al., “ Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand.” Proc Natl Acad Sci U S A. Mar. 30, 1999;96(7):3540-5.
Huber DM, et al., “Androgens suppress osteoclast formation induced by RANKL and macrophage-colony stimulating factor.” Endocrinology. Sep. 2001;142(9):3800-8.
Ikeda T, et al., “Determination of three isoforms of the receptor activator of nuclear factor-kappaB ligand and their differential expression in bone and thymus.” Endocrinology. Apr. 2001;142(4):1419-26.
Ito S, et al., “Crystal structure of the extracellular domain of mouse RANK ligand at 2.2-A resolution.” J Biol Chem. Feb. 22, 2002;277(8):6631-6.
Kaneda T, et al., “Endogenous production of TGF-beta is essential for osteoclastogenesis induced by a combination of receptor activator of NF-kappa B ligand and macrophage-colony-stimulating factor.” J Immunol. Oct. 15, 2000;165(8):4254-63.
Kitazawa R, and Kitazawa S. “Vitamin D(3) augments osteoclastogenesis via vitamin D-responsive element of mouse RANKL gene promoter.” Biochem Biophys Res Commun. Jan. 18, 2002;290(2):650-5.
Kitazawa R, et al., “Promoter structure of mouse RANKL/TRANCE/OPGL/ODF gene.” Biochim Biophys Acta. Apr. 14, 1999;1445(1):134-41.
Kong YY, et al., “Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand.” Nature. Nov. 18, 1999;402(6759):304-9.
Lacey DL, et al., “Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.” Cell. Apr. 17, 1998;93(2):165-76.
Lam J, et al. “TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RA
Desjarlais John R.
El Yazal Jamal
Hubert Rene S.
Marshall Shannon A.
Allen Marianne P.
Deberry Regina
Morgan & Lewis & Bockius, LLP
Silva Robin M.
Xencor, Inc.
LandOfFree
Variants of RANKL protein does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Variants of RANKL protein, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Variants of RANKL protein will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2795905